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ABSTRACT
The use of oligonucleotide-assisted cleavage and
ligation (ONCL), a novel approach to the capture
of gene repertoires, in the construction of a phage-
display immune antibody library is described. ONCL
begins with rapid amplification of cDNA ends to
amplify all members equally. A single, specific cut
near 50 and/or 30 end of each gene fragment (in single
stranded form) is facilitated by hybridization with
an appropriate oligonucleotide adapter. Directional
cloning of targeted DNA is accomplished by ligation
of a partially duplex DNA molecule (containing sui-
table restriction sites) and amplification with primers
inconstantregions.Todemonstrateutilityandreliab-
ility of ONCL, a human antibody repertoire was
cloned from IgG mRNA extracted from human
B-lymphocytes engrafted in Trimera mice. These mice
were transplanted with peripheral blood lympho-
cytes from Candida albicans infected individuals
and subsequently immunized with C.albicans glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH). DNA
sequencing showed that ONCL resulted in efficient
capture of gene repertoires. Indeed, full representa-
tion of all VH families/segments was observed show-
ing that ONCL did not introduce cloning biases for or
against any VH family. We validated the efficiency of
ONCL by creating a functional Fab phage-display lib-
rary with a size of 3.3 · 10
10 and by selecting five
unique Fabs against GAPDH antigen.
INTRODUCTION
Phage-display has been used to generate and select libraries of
antibody fragments in scFv or Fab formats (1–7). Non-
immune or immune antibody repertoires are routinely cloned
from human B-lymphocyte mRNAs using RT–PCR of VH and
VL genes (8–14). Although the use of PCR technology (15,16)
has accelerated the cloning, sequencing, and characterization
of genes, the cloning and sequencing of Ig variable (V) genes
by PCR has been challenging, primarily due to the great
diversity of Ig V region genes. Indeed, the use of PCR priming
regions on each side of the targeted Ig V region compromises
the equal ampliﬁcation of all immunoglobulin mRNAs
because there are no constant 50 end mRNA sequences.
Over the last decade, several methods have been established
to capture the widest repertoire of immunoglobulin genes. One
PCR-based cloning approach of immunoglobulin cDNAs used
degenerate consensus sequences as 50 end primers (17). This
method risks introducing biases in the capture of the different
Ig family repertoires, largely due to the varying efﬁciency of
mRNA ampliﬁcation among these sequences. As a result, the
ﬁrst 6–8 amino acids of the variable heavy and light chain
sequence can differ from the original mRNA sequence which
can affect the distribution, the expression and the functionality
(antigen binding) of the antibody (18,19). Anchor PCR, a
second and more general method, tails the 30 end of the
ﬁrst strand of cDNA with oligo(dG) to provide a template
for reverse priming with oligo(dC) (20,21). In this case, the
length of the tail formed with terminal deoxynucleotidyl trans-
ferase may vary from a few bases to >200 bases, complicating
identiﬁcation of the appropriate size of the ampliﬁed cDNA.
Since all methods described above use PCR technology to
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doi:10.1093/nar/gni080capture antibody diversity, they potentially carry biases intro-
duced by PCR oligonucleotides due to the lack of sequence
uniformity in the antibody V-region.
Alternative antibody cloning strategies that do not rely on
the priming of oligonucleotides within the antibody V-region,
such as PCR adaptors (22), CapFinder (23) and rapid ampli-
ﬁcation of cDNA ends (RACE) technologies (24,25), have
been described. However, those techniques are subject to
high background interference and do not provide antibody
gene expression in the correct reading frame. Indeed,
Schramm et al. (26) have described residual primer contam-
ination from the initial reaction resulting in the ampliﬁcation
of non-desired cDNA fragments. To address such contamina-
tion problems, Roeder (27) implemented the RACE approach
with a solid-phase cDNA synthesis.
In this paper, we describe a method to efﬁciently clone and
capture families of genes, in particular antibody genes. This
technique (i) involves ampliﬁcation using oligonucleotides
that prime outside the variable part of the genes (antibody
V-region), (ii) has low background, and (iii) allows expression
of the captured genes in a correct reading frame.
The utility of this new method is illustrated by the con-
structionofanimmunephage-displayantibodylibrarydirected
against Candida albicans cell-wall associated glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) protein. GAPDH was
selected as the target protein because it is expressed on the
surface of Candida cells. Therefore, C.albicans-speciﬁc anti-
GAPDHantibodiesarepotentialtherapeuticleadsforthetreat-
ment of Candida infections. We have used the Trimera mouse
technology to obtain an immunized human antibody repertoire
(28–30). Trimera mice engrafted with functioning human
peripheral blood lymphocytes (PBLs) and immunized with a
speciﬁcantigengenerateantigen-speciﬁchumanantibodies.In
this pilot study, we used Trimera mice engrafted with human
PBLs of C.albicans-infected patients. The mice were sub-
sequently immunized with a recombinant baculovirus-
produced C.albicans GAPDH in order to obtain a human
anti-C.albicans GAPDH immune antibody repertoire. The
oligonucleotide-assistedcleavageandligation(ONCL)method
was then used to clone the human V genes, and a Fab phage-
displaylibrarywith 33billionsFabcloneswasbuilt.Because
allofthePCRprimingsitesareoutsidethevariableregions,the
methoddoesnotintroducevariationsinefﬁciencyofampliﬁca-
tion for different Ig mRNAs. In addition, as the cleavage step
involves no ampliﬁcation, the generation of biases is unlikely.
TheefﬁciencyofthetechnologywasfurtherdemonstratedbyIg
genesequencingfollowedbyselectionofanti-GAPDHspeciﬁc
antibodies.
MATERIALS AND METHODS
Expression, purification and biotinylation of
C.albicans GAPDH
The full-length cDNA of C.albicans GAPDH was provided by
Dr D. Gozalbo (University of Valencia, Spain) (31) and
expressed in the Baculovirus gold system (Pharmingen).
GAPDH was puriﬁed via nickel agarose chromatography
(Qiagen,Hilden,Germany).ThebiotinylationratioforGAPDH
was ﬁve molecules of NHS-SS-biotin (Pierce) per molecule
of antigen, in accord with the supplier’s recommendations.
Biotinylation was checked using non-reducing PAGE and
conﬁrmed by western blot using streptavidin horseradish
peroxidase for detection.
Peripheral blood lymphocytes
Human PBLs were obtained by leukopheresis from four
female donors (age 18–55) who had experienced at least
one episode of vaginitis caused by Candida species. Immune
response to C.albicans GAPDH in each donor was evidenced
by the presence of anti-GAPDH IgG-speciﬁc antibodies in the
serum, as well as signiﬁcant T-cell proliferative response. The
PBLs were separated on Ficoll IsoPrep (Robbins Scientiﬁc
Corporation), washed twice, counted and re-suspended in
phosphate-buffered saline (PBS). For in vitro activation,
one-quarter of the cells were incubated for 16 h in RPMI
medium supplemented with 10% fetal calf serum (FCS)
(Biological Industries), glutamine (200 mM), sodium pyruvate
(100 mM), 1% Eagle’s non essential amino acids, 0.1%
HEPES buffer and b-mercaptoethanol in the presence of
10 mg/ml GAPDH and Pokeweed mitogen (Gibco) diluted
1:100.
Mice
BALB/c mice, 6–10 weeks old, were obtained from the
Weizmann Institute Animal Breeding Center (Rehovot,
Israel). All mice were fed sterile food and given acidiﬁed
water containing ciproﬂoxacin (20 mg/ml) (Bayer, Leverku-
sen, Germany). Mice were injected daily with 1 mg Fortum
(Glaxo Operations UK, Greenford, England) intraperitoneally
(i.p.) for 5 days post-bone marrow transplantation.
The Trimera system
BALB/c mice were exposed to split-dose total body irradiation
(4Gyfollowed3dayslaterby10–11Gy),fromagammabeam
150 s
60Co source produced by Atomic Energy of Canada
(Kanata, Ontario, Canada) with focal skin distance of 75 cm
and a dose rate of 0.7 Gy/min. Following irradiation, each
recipient mouse was immediately injected intravenously
(i.v.) with 4–6 · 10
6 of SCID/NOD bone marrow cells and
i.p. with 100 · 10
6 human PBLs (28). On the day of PBL
transplantation, Trimera mice were immunized once
i.p. with 150 mg per mouse of GAPDH absorbed in 0.15%
aluminum hydroxide gel (Merck, Darmstadt, Germany). One
day after transplantation, mice were boosted with 15 · 10
6
in vitro activated human PBLs and 75 mg per mouse GAPDH.
On the following day, mice were boosted again with 150 mg/
mouse GAPDH. Animals were bled from the retro-orbital vein
using heparin-coated glass capillaries. Plasma was kept for
human immunoglobulin determination. Animals were killed
by cervical dislocation; their spleens were removed, cut into
pieces, then pressed through stainless steel sieves to make a
cell suspension in PBS.
Fluorescence-activated cell sorter (FACS) analysis of
engrafted human cells
Spleen cells were incubated for 30 min on ice with mouse anti-
human CD45-ﬂuorescein isothiocyanate (pan-leukocyte anti-
gen, Caltag Laboratories, South San Francisco, CA). After
washing, ﬂuorescent analysis was performed on a FACScan
analyzer (Becton Dickinson, Mountain View, CA).
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antigen specific antibodies
Trimera mice sera were tested for total human immuno-
globulin and for antigen-speciﬁc antibodies. Total human
immunoglobulin was quantiﬁed by sandwich enzyme linked
immunosorbent assay (ELISA) using puriﬁed goat F(ab)2 anti-
human IgG (Chemicon International, Temecula, CA) as the
capture agent (1 mg/well) and puriﬁed goat anti-human IgG
peroxidase conjugates (Chemicon International) as a detection
reagent. Puriﬁed human IgG was used as the standard (Sigma,
Rehovot, Israel). Concentration of anti-GAPDH antibodies in
human or mice sera was determined by an antigen-speciﬁc
ELISA. Microtiter plates (Nunc, Roskilde, Denmark) were
coated with 10 mg/ml of GAPDH in PBS for 18 h at 4 C.
The plates were blocked with PBS, 0.1% Tween-20 and 20%
FCS, for 1 h at room temperature and reacted with human sera
or Trimera mice sera diluted 1:20 and 1:200, respectively, for
2 h at room temperature. Bound anti-GAPDH antibodies were
detected with a 1:10 000 dilution of goat anti-mouse/human
peroxidase conjugated polyclonal antibodies (Chemicon Inter-
national). Following 1 h incubation and subsequent washings,
substrate solution (TMB, Chemicon International) was added.
Results were read at a wavelength of 450 nm using an ELISA
reader.
RNA extraction and mRNA isolation
Spleens from 12 immunized Trimera mice were either frozen
in liquid nitrogen immediately after removal from the animal
and placed at  70 C for long-term storage or immersed in
1.6mlofRNAlater(Qiagen)andkeptat4 Cfornolongerthan
1 month. Spleens were homogenized in 4 ml of RNAzol B,
using a Kinematica Polytron PT 2100 homogenizer. Chloro-
form was added to each sample up to 20% of the ﬁnal volume
and the samples were left on ice for 5 min. Samples were then
centrifuged for 15 min at 4 C and an equal volume of isopro-
panol was added to the upper phase. The RNA was left to
precipitate on ice for 15 min, a step that was followed by
15 min of centrifugation at 21 900 g. The RNA pellet was
washed with 75% ethanol, dried and re-suspended in 100 mlo f
DEPC-treated water. Optical density was measured using
GeneQuant-pro (Amersham Pharmacia), and the RNA integ-
rity was visualized on a 1.2% agarose TAE gel. One-tenth
volume of 3 M sodium acetate and 2.5 vol of ethanol were
added to the samples and stored at  70 C. Recovery of the
RNA was carried out by 10–15 min centrifugation at 4 C
followed by 70% ethanol wash of the pellet and
re-suspension in DEPC-treated water to the desired volume.
The RNA amount recovered from each spleen ranged between
80 and 220 mg. For mRNA isolation, 4 mg of total RNA from
each of the 12 spleen samples was submitted to the Poly-
ATtract
  mRNA Isolation Systems (Promega) according to
the manufacturer’s instructions.
Capture and amplification of variable region genes
Cleavage of the pyrophosphate bond of the 50 terminal methyl-
ated guanine nucleotide mRNA ‘cap’ was achieved using
Tobacco Acid Pyrophosphatase enzyme (TAP) (Epicentre
Technologies): in practice, 400 ng mRNA was treated
for 60 min at 37 C with 4 U of TAP in TAP reaction buffer
[50 mM sodium acetate (pH 6.0), 1 mM EDTA, 0.1%
b-mercaptoethanol and 0.01% Triton X-100 supplemented
with 160 U of RNAsin (40 U/ml) (Promega)]. Decapped
mRNA was then puriﬁed over an RNAeasy column (Qiagen).
Next,100ngofdecappedmRNAwasheat-denatured for5min
at 65 C in the presence of 240 ng (50· molar excess) of
an RNA adapter (50-GCUGAUGGCG AUGAAUGAAC
ACUGCGUUUG CUGGCUUUGA UGAAA-30), then cooled
for 2 min on ice. Ligation was performed for 1 h at 37 C
using 10 U of T4 RNA ligase in ligation buffer (Promega),
supplemented with 10 U RNAsin (40 U/ml) (Promega) and
was followed by puriﬁcation over a RNAeasy column (Qia-
gen). Subsequently, 50 ng of the ligated RNA was converted
into cDNA: 100 pmol oligo(dT)15 primer (Roche), buffer and
DTT were added to the mixture according to the supplier’s
instructions (Life Technologies, Inc.), as well as 400 mM
dNTPs (Amersham), 40 U of RNAsin (40 U/ml; Promega)
and 200 U of Moloney murine leukemia virus reverse tran-
scriptase (Life Technologies, Inc.) in a total volume of 25 ml.
After 1 h at 42 C, enzyme was heat-inactivated at 70 C for
15 min, and cDNA was immediately used for PCR ampliﬁca-
tion. Primary PCR ampliﬁcation was carried out on 3 mlo ft h e
cDNA reaction volume using a 50 primer complementary to
the RNA adapter tailed sequence (Outer Inv primer) combined
with a 30 primer either complementary to the human IgG-
derived heavy chain (CH1IgGXTLfor) or to the k-o rl-
light chain constant regions (HuCkforAsc, Cl2,7forAsc).
PCR was performed in a volume of 25 ml using the Advantage
2 PCR enzyme system (Clontech) and 10 pmol of each primer
for 35 cycles (1minat95 C,1min at 60 C and 2min at68 C).
The PCR products were re-ampliﬁed with a combination of a
50 end biotinylated nested primer (Inner Inv primer) and a 30
end NheI-tagged nested CH1 reverse primer for the heavy
chains, and k-o rl-light chain constant region primers ident-
ical to the ﬁrst PCR. Similar to primary PCR, the second PCR
was performed in a volume of 50 ml using the Advantage
2 PCR enzyme system (Clontech) and 10 pmol of each primer
for25 cycles (1min at95 C,1min at60 C and2min at68 C);
100 reactions were performed. All biotinylated products were
puriﬁed from an agarose gel with the GFX extraction kit
(Amersham).
ONCL cloning method
(i) DNA immobilization. An aliquot of 6 mg of double-
stranded DNA (dsDNA) biotinylated on the 50 end of the
top strand was bound to 900 ml of streptavidin-coupled mag-
netic beads (Seradyn) in 1 ml B&W buffer [5 mM Tris–HCl
(pH 7.5), 0.5 mM EDTA, 1 M NaCl and MQH2O] for 30 min
underrotationatroomtemperature.UnboundDNAwaswashed
away two times with 1 ml of 1· B&W buffer.
(ii) Conversion of DNA to single-stranded (ss) form. DNA
immobilized on the beads was incubated with 900 ml 0.1 M
NaOH for 3 min, washed once with 1 ml of 0.01 M NaOH
followed by one additional washing step using 1 ml Tris–NaCl
buffer [10 mM Tris–HCl (pH 7.5), 100 mM NaCl].
(iii) (a). ONCL cleavage of the light chains. During a con-
trolled temperature decrease (from 90 to 50 Ca t1  C per 45 s),
single-stranded DNA (ssDNA) was annealed to the set of
adapters shown in Table 1 (40· molar excess for k chains
and 80· molar excess for l chains) in the appropriate restric-
tion enzyme buffer (New England Biolabs). After annealing,
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complex bound on beads was then incubated in 250 ml of NEB
restriction enzyme buffer containing 15 U BsmAI/mg ssDNA
(for k chains) or 50 U HinfI/mg ssDNA (for l chains) for 1 h at
the respective cleavage temperature (55 C for BsmAI and
50 C for HinfI) in order to release the light chain gene
fragment into the supernatant.
(iii) (b). ONCL cleavage of the heavy chains. First, 0.1 M
NaOH-denatured ssDNA was annealed to a set of adapters
shown in Table 1 (35· molar excess for PvuII cleavage
and 10· molar excess for AvaII cleavage) in presence of
1· NEB4 buffer (New England Biolabs) with controlled tem-
perature decrease (from 90 to 50 Ca t1  C per 45 s). After
annealing, the unbound adapters were washed away. The
Table 1. Oligonucleotide primers, adapters and bridge–extenders used for library construction
Oligonucleotide name Oligonucleotide sequence Restriction enzyme
Outer Inv primer GCTGATGGCGATGAATGAAC
Inner Inv primer GAACACTGCGTTTGCTGGC
Adapter for Vl family 1 GAGGGTGGCT GAGTC AGCAC HinfI
Adapter for Vl family 2 GAGGCAGGCT GAGTC AGGGC HinfI
Adapter for Vl family 3 (1) GCAGGGTCCT GAGTC AGCTC HinfI
Adapter for Vl family 3 (2) GAGGGTGGCT GAGTC AGCTC HinfI
Bridge for Vl family 1 GGCTGAGTCAAGACGCTCT GTGCAC TTCGCTGTCGAGG ApaLI
Extender for Vl family 1 CCTCGACAGCGAA GTGCAC AGAGCGTCTTG ApaLI
Bridge for Vl family 2 GGCTGAGTCAAAGCGCTCT GTGCAC TTCGCTGTCGAGG ApaLI
Extender for Vl family 2 CCTCGACAGCGAA GTGCAC AGAGCGCTTTG ApaLI
Bridge for Vl family 3 (1) GGCTGAGTCAATTCGCTCT GTGCAC TTCGCTGTCGAGG ApaLI
Extender for Vl family 3 (1) CCTCGACAGCGAA GTGCAC AGAGCGAATTG ApaLI
Bridge for Vl family 3 (2) GGCTGAGTCAATTCGTACT GTGCAC TTCGCTGTCGAGG ApaLI
Extender for Vl family 3 (2) CCTCGACAGCGAA GTGCAC AGTACGAATTG ApaLI
ONPlePCR CCTCGACAGCGAA GTGCAC AG ApaLI
Cl2forAsc ACCGCCTCCACCG GGCGCGCC TTATTATGAACATTCTGTAGGGGCCACTG AscI
Cl7forAsc ACCGCCTCCACCG GGCGCGCC TTATTAAGAGCATTCTGCAGGGGCCACTG AscI
Adapter for Vk family 1 (1) GGGAGGAT GGAGAC TGGGTC BsmAI
Adapter for Vk family 1 (2) GGGAAGAT GGAGAC TGGGTC BsmAI
Adapter for Vk family 2 GGGAGAGT GGAGAC TGAGTC BsmAI
Adapter for Vk family 3 (1) GGGTGCCT GGAGAC TGCGTC BsmAI
Adapter for Vk family 3 (2) GGGTGGCT GGAGAC TGCGTC BsmAI
Adapter for Vk family 4 GGGAGTCT GGAGAC TGGGTC BsmAI
Bridge for Vk family 1 (1) GGGAGGATGGAGACTGGGTCATCTGGATGTCTT GTGCAC TGTGACAGAGG ApaLI
Bridge for Vk family 1 (2) GGGAAGATGGAGACTGGGTCATCTGGATGTCTT GTGCAC TGTGACAGAGG ApaLI
Bridge for Vk family 2 GGGAGAGTGGAGACTGGGTCATCTGGATGTCTT GTGCAC TGTGACAGAGG ApaLI
Bridge for Vk family 3 (1) GGGTGCCTGGAGACTGGGTCATCTGGATGTCTT GTGCAC TGTGACAGAGG ApaLI
Bridge for Vk family 3 (2) GGGTGGCTGGAGACTGGGTCATCTGGATGTCTT GTGCAC TGTGACAGAGG ApaLI
Bridge for Vk family 4 GGGAGTCTGGAGACTGGGTCATCTGGATGTCTT GTGCAC TGTGACAGAGG ApaLI
Extender for all k bridges CCTCTGTCACA GTGCAC AAGACATCCAGATGACCCAGTCTCC ApaLI
KaPCRt1 CCTCTGTCACA GTGCAC AAGAC ApaLI
HuC kforAsc ACCGCCTCCACCG GGCGCGCC TTATTAACACTCTCCCCTGTTGAAGCTCTT AscI
Adapter for VH1 CCAGACTGCAC CAGCTG CACC PvuII
Adapter for VH3 (1) CCAGACTCCAC CAGCTG CACC PvuII
Adapter for VH3 (2) CCAGACTCCAA CAGCTG CACC PvuII
Adapter for VH4 (1) CCCGACTCCTG CAGCTG CACC PvuII
Adapter for VH4 (2) CCCGACTCCTG CAGCTG CAGC PvuII
Adapter for VH6 CCTGACTGCTG CAGCTG TACC PvuII
Adapter for VH7 CCAGACTGTAC CAGCTG GACC PvuII
Bridge for VH1 GACTGCACCAGCTGAACTTCAGCCAT GGCCGGCTGGGCC TTCTACTAAACAGTC SfiI
Bridge for VH3 (1) GACTCCACCAGCTGAACTTCAGCCAT GGCCGGCTGGGCC TTCTACTAAACAGTC SfiI
Bridge for VH3 (2) GACTCCAACAGCTGAACTTCAGCCAT GGCCGGCTGGGCC TTCTACTAAACAGTC SfiI
Bridge for VH4 GACTCCTGCAGCTGAACTTCAGCCAT GGCCGGCTGGGCC TTCTACTAAACAGTC SfiI
Bridge for VH7 GACTGTACCAGCTGAACTTCAGCCAT GGCCGGCTGGGCC TTCTACTAAACAGTC SfiI
Bridge for VH6 GACTGCTGCAGCTGAACTTCAGCCAT GGCCGGCTGGGCC TTCTACTAAACAGTC SfiI
Extender for all VH GACTGTTTAGTAGAA GGCCCAGCCGGCC ATGGCTGAAGTTCAG SfiI
HCP2PCR2 GACTGTTTAGTAGAAGGCCCAGCC
Adapter for VH2 (1) CACCAGCGTA GGACC AGACTCCTT AvaII
Adapter for VH2 (2) CACCAGCACA GGACC AGACTCCTT AvaII
Bridge for VH2 (1) AGCGTAGGACCGCTTTCTTTAAGAGTAATTTGGGCCAT GGCCGGCTGGGCC TAGA-
CAAGTGTGGAAG
SfiI
Bridge for VH2 (2) AGCACAGGACCGCTTTCTTTAAGAGTAATTTGGGCCAT GGCCGGCTGGGCC TAGA-
CAAGTGTGGAAG
SfiI
Extender for VH2 CTTCCACACTTGTCTA GGCCCAGCCGGCC ATGGCCCAAATTACTCTTAAA-
GAAAGCG
SfiI
HC2PCRAva CTTCCACACTTGTCTAGG
NheICH1IgGfornested GCCGATCTAG GCTAGC GGGAAGACCGATGGGCCCTTGG NheI
Ch1IgGXTLfor GCTGCTGAGGGAGTAGAGTGG
Note: All sequences are written from 50 to 30. Enzymatic recognition sites are in italics. Arabic numbers in parentheses indicate pairings where multiple sequences
occur in the germlines within a family.
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250 ml of NEB restriction enzyme buffer containing 50 U
PvuII/mg ssDNA or 80 U AvaII/mg ssDNA for 1 h at 50 C
in order to release the heavy chain gene fragments in the
supernatant.
(iv) Bridge–extender ligation. To create partially dsDNA,
500 pmol of a set of oligonucleotides were mixed with
500 pmol of the complementary set of oligonucleotides
(Table 1, bridge and extender) at 95 C and then cooled to
16 C (at 1 C per 45 s) in 1· T4 DNA ligase buffer. Sub-
sequently, 100 ng of the column-puriﬁed ssDNA was ligated
to 100· molar excess of bridge–extender duplex. The ligation
was performed in 75 ml using 200 U of T4 DNA ligase (NEB)
and carried out for 16 h at 16 C. After ligation, the bridge–
extender–DNA complex was puriﬁed using Qiagen PCR
puriﬁcation kit (Qiagen) and eluted in 50 ml EB buffer
(10 mM Tris–HCl, pH 8.0).
(v) Ampliﬁcation and cloning of the bridge–extender DNA.
This step was performed for 13 cycles (light chains) or
15 cycles (heavy chains) in order to maintain maximal divers-
ity in a 25 ml volume format using Advantage 2 DNA poly-
merase (Clontech) (1 min at 95 C,1 min at 60–65 C and 2 min
at 68 C). Sequences of the primers asserting restriction
enzyme sites for directional cloning of the fragments are dis-
closed in Table 1 (KaPCRt1 and HuCkforAsc for k light
chains; ONPlePCR and Cl2,7forAsc for l light chains;
HCP2PCR2 (PvuII) or HC2PCRAva (AvaII) and NheI-
CH1IgGfornested for heavy chains).
Construction of the Fab library
For the construction of the primary light chain repertoires, the
VkCk and VlCl PCR products, appended with the ApaLI and
AscI restriction sites, were digested using 50 U/mg of each
enzyme and agarose gel puriﬁed. Using T4 DNA ligase (NEB),
1.5 mg of each resulting DNA fragment was ligated into 2.5 mg
of similarly cut phagemid vector pMID21 (Figure 1). Sub-
sequently, 400 ng of desalted l-ligation mixture and 500 ng
of the k mixture were electroporated separately into the
Escherichia coli strain TG1 using 10 ng of ligation mixture
per electroporation event. The Fab library was obtained by
cloning of the VH repertoire into each of the light chain sub-
libraries. The VHCH1 PCR products, appended with the SﬁI
and NheI restriction sites, were digested using 50 U/mg of each
enzyme and agarose gel puriﬁed. Using T4 DNA ligase (NEB),
6.7 mg of the VHCH1 DNA fragments were ligated into 5 mgo f
the similarly cut l or k sublibrary DNA. Finally, 1250 ng of
desalted lHC-ligation mixture and 1250 ng of the kHC one
were electroporated into the E.coli strain TG1 using 25 ng of
ligation mixture per electroporation event.
Figure 1. Overview of the library construction—combination of Trimera mouse technology, ONCL method and phage-display. Lower part shows a schematic
representationofphagemidvectorpMid21usedfordisplayofantibodyFabfragments. ThisvectorisderivedfrompCES1(8).Thepolylinkerregioncomprisestwo
signal sequences, Ck domain, ribosome binding site (rbs), CH1 domain, hexahistidine tag and a c-myc-derived sequence (His/myc tags). Light chain genes can be
clonedasApaLI–AscI(1,2)fragmentsandvariableheavychaingenesasSfiI–NheI(3,4)fragments.TheMluI(5)restrictionsitesflankingbothsitesoftheM13gene
IIIstumpenabletheremovalofthestumpanchordomain,whichallowstheproductionofsolubleFabfragments.Expressionofthebicistronicoperonisundercontrol
of the LacZ promoter (pLacZ).
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The rescue of the phagemid particles with helper phage M13–
KO7 was performed according to Marks et al. (3) on a 2.3-l
scale. For selection, 10
13 phages were used with GAPDH anti-
gen immobilized on immunotubes (Maxisorp tubes, Nunc) (3)
orwithsolublebiotinylatedGAPDH(31).Theantigenconcen-
tration for selection on immunotubes was 70 mg/ml during all
three rounds and 580 and 200 pmol for selection with the biot-
inylated antigen for round 1 and rounds 2 and 3, respectively.
Screening and sequencing of clones
Phage-displaying Fabs were produced from 94 individual
clones as previously described (3). Culture supernatants
were tested by ELISA with biotinylated antigen indirectly
captured via immobilized BSA–streptavidin. Coating of the
ELISA plates and the assay itself were performed as previ-
ously described (8). Fabs from clones giving a positive signal
in ELISA (more than two times > background) were ampliﬁed
using 50 and 30 backbone primers, and the PCR products were
sequenced for both light and heavy chains. To allow soluble
Fab expression, the positive phage antibodies were then
recloned in order to remove the Fab-fused gene III anchor
fragment (Figure 1). In practice, 1 mg of plasmid DNA was
digested using 10 U/mg MluI restriction enzyme. The gene III
anchor domain was then removed by agarose gel puriﬁcation.
Resulting phagemid vector was then ligated using T4 DNA
ligase (NEB) and transformed into E.coli TG1 strain.
Large-scale induction of soluble Fab fragments from indi-
vidual clones was ﬁrst performed on a 50 ml scale in 2· TY
containing 100 mg/ml ampicillin and 2% glucose. After over-
night growth at 30 C, 500 ml of 2· TY with 100 mg/ml ampi-
cillinand0.1%glucosewereseededwiththisovernightculture
to reach an OD600 of 0.05 (1/100). After growth at 37 Ct oa n
OD600 of 0.8, the medium was supplemented with 1 mM iso-
propyl-1-thio-b-D-galactopyranoside and cells were incubated
at 30 C for additional 4 h. Bacteria were then pelleted by cent-
rifugation (10 min at 2934 g); periplasmic fractions were pre-
pared by resuspending the cell pellet in 5.3 ml of ice-cold TES
(0.2MTris,0.5mMEDTAand0.5Msucrose,pH8.0).Afteran
incubation of 10 min on ice, TES concentration was decreased
byadding1volofTES/H2O(1:3)foradditional20minincuba-
tion on ice. The periplasmic fraction was then collected by
spinning the cell debris at 8000 g for 20 min at 4 C. Crude
extracts were then dialyzed overnight over PBS at 4 C.
VH distribution analysis
This analysis was performed on the VH gene samples captured
andampliﬁedfollowingtheproceduresdescribedabove.How-
ever, the ampliﬁcation step was performed with identical but
unbiotinylated primers. Thirty nanograms of this VH gene
PCR product were cloned using TOPO TA Cloning
  for
sequencing (Invitrogen) according to the manufacturer’s
instructions. The sequences of 115 clones were determined.
RESULTS
Immunization of Trimera mice with C.albicans GAPDH
Therationaleforbuildingaphage-displaylibraryfromimmun-
ized Trimera mice is that display on phage and selection of the
IgG human immune response in Trimera mice will allow
selection of the desired antibodies at a higher rate than by
direct screening of hybridomas from these mice. Thus, Tri-
mera mice were prepared by transplantation of human PBLs
obtained from four individual leukopheresis donors into irra-
diated BALB/c mice, radio-protected with bone marrow from
SCID mice. Soluble C.albicans GAPDH (baculovirus pro-
duced) was used to boost the Trimera mice immune response
(Figure 1). Human cell engraftment measured as the percent-
age of human CD45
+ cells in Trimera mice spleens showed
that mouse spleens contained 0.8–28% of human CD45
+
cells. The presence of human C.albicans GAPDH-speciﬁc
IgG antibodies was conﬁrmed in immunized Trimera mice
sera by ELISA on days 14–17 after transplantation. The
speciﬁc human IgG activity (nanograms anti-C.albicans
GAPDH-speciﬁc antibodies per milligram human IgG) ran-
ged between 300 and 1800 ng/mg in different Trimera mice
as compared with  40 ng/mg in donors’ sera. This suggests
an induction of the immune response to GAPDH in the
Trimera mice.
Library construction
Capture of V-gene diversity. A Fab phage antibody library was
builtfromthespleenRNAof12respondingmice.The12RNA
samples were processed separately. The capture of V genes
was performed in two main steps. First, decapped full-length
mRNA extracted from spleen cells of Trimera mice was tailed
at the 50 end with a synthetic RNA oligonucleotide before the
reverse transcription was performed. For speciﬁc capture and
ampliﬁcation of antibody genes, 30 end primers complement-
ary to the constant regions of the antibody genes and 50-biot-
inylated primers complementary to the attached synthetic
sequence (Figure 2A) were used. Priming at this synthetic
50 sequence avoids the use of primers within the variable
regions of the antibody genes that could generate biases
against rare subclasses of V genes or ones mutated at the
priming sites. Only IgG-derived VH segments were ampliﬁed
from newly synthesized cDNAs using a primer located in the
CH1 of IgG1-4. From this step onwards, the 12 samples, pre-
viously processed separately, were pooled in equal amounts.
The ONCL method. The VH and VL genes are cloned using a
novel technology, referred to as ‘ONCL’, which is depicted in
Figure 2A. First, dsDNA biotinylated on one strand is immob-
ilized on streptavidin-coated magnetic beads. ssDNA is then
prepared by alkaline denaturation. Short dsDNA segments are
created by annealing of the oligonucleotide to the immobilized
ssDNA providing a restriction site that can be recognized by
the related restriction enzyme. High temperatures (>50 C)
were used for the cleavage in order to avoid secondary struc-
tures in the ssDNA that could result in cleavage at other
instances of the site recognized by the restriction enzyme.
The cleaved ssDNA is then prepared for cloning by ligation
of a partially duplexed synthetic DNA adapter, referred to as a
bridge–extender. The bridge–extenders encode sequences of
50 human antibody V genes that supply a useful restriction
enzyme recognition site and bring the captured sequences into
proper register. The 30 terminal single-stranded part of the
bridge–extender is complementary to the 50 end of the cleaved
ssDNA fragments. Finally, the ligated product is ampliﬁed
using primers at the 50 end of ligated DNA (non-V gene
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genes. Each primer introduces a restriction enzyme recogni-
tion site so that the Ig repertoire can be cloned into the display
vector in the proper orientation and reading frame.
In order to cover as many human V-region gene segments as
possible, a set of several Vl (4), Vk (6) or VH (9) oligonuc-
leotides annealing to framework 1 of antibody genes were
designed (Table 1). The enzyme cleavage location was chosen
very near the 50 end of the V-region to avoid altering the
original antibody sequences as presented in the example of
ONCL for Vl family 1 genes (Figure 2B). The oligonuc-
leotides were designed so that they allow efﬁcient capture
of all commonly used V-gene segments. Their design was
based on the most recent sequence information provided by
V-base (http://vbase.mrc-cpe.cam.ac.uk/). For the light chains,
primers for only the main families 1, 2 and 3 were designed,
representing  90% of the light chain repertoire (32). An
analysis of the matching efﬁciency of each oligonucleotide
to germ-line genes was performed for the heavy and light
chains. The set of oligonucleotides we designed allows the
capture of all VH germ-line gene segments, except segments 1-
03 and 4-34 (which contain neither PvuII nor AvaII sites),
representing 1 and 2.5% of the re-arranged heavy chain rep-
ertoire, respectively (32).
The cleavage results of the spleen-derived Vl,V k and VH
repertoires are presented in Figure 3. l Light chains were
captured using a set of four oligonucleotides containing a
HinfI enzymatic cleavage site. Following digestion of the
single-stranded l light chains immobilized on beads by
HinfI (left panel A, column 2), a cleaved fragment of
 600 bp appeared in the supernatant fraction (column 3).
Gel densitometry analysis revealed that 70% of captured l
light chain molecules were recovered (compare column 2 with
column 3). K light chains were captured using a set of six
A
.
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Following digestion of the single-stranded k light chains
immobilized on beads by BsmAI (right panel A, column 2),
a cleaved fragment of  600 bp appeared in the supernatant
fraction (column 3). Gel densitometry analysis revealed that
90%ofcaptured k lightchain moleculeswere recovered(com-
pare column 2 with column 3). All heavy chain families except
family 2 were captured using a set of seven oligonucleotides
containing a PvuII enzymatic cleavage site (VH families
1, 3, 4, 5, 6 and 7), while VH family 2 was captured using
a set of two oligonucleotides carrying an AvaII restriction
recognition site. Following digestion of the single-stranded
heavy chains immobilized on beads by PvuII enzyme (left
panel B, columns 1 and 2), a cleaved fragment of 400 bp is
released in the supernatant fraction (column 3). ssDNA left on
the beads was then submitted to an AvaII cleavage (right panel
B, columns 1and 2),and a fragmentof 400 bp was cleaved and
collected in the supernatant (column 3). Gel densitometry
analysis of both gels revealed that, in total, 85% of captured
heavy chain molecules were cleaved. PvuII-cleaved V genes
were combined with AvaII-cleaved genes in the ratio 80:15,
which is the observed ratio of the genes so cleaved.
All single-stranded cleaved fragments (l, k and heavy
chains) were then ligated to partially double-stranded oligo-
nucleotides (bridge–extenders), of which the 30 end is com-
plementary to the 50 end of the cleaved products (Table 1). In a
ﬁnal ampliﬁcation (13–15 cycles) of the ligated V genes, pri-
mers appended with restriction recognition sites enable the
directional cloning of the V genes into the expression vector
(ApaLI–AscI for light chains and SfI–NheI for heavy chains).
Phagemid library construction. A two-step cloning procedure
was used to construct the library. The ONCL-cleaved Vk and
Vl repertoires were cloned separately to maintain the V-gene
B
Figure 2. TheONCLtechnology.(A)SchematicoutlineoftheONCLtechnology.RACE:decappedmRNAisligatedtoaRNAadapter,thenconvertedtocDNAby
RT–PCR. cDNA is then amplified using a 50-biotinylated primer complementary to the adapter sequence combined with a 30-primer either complementary to the
human IgG-derived heavychain constantregionor to the lightchain constantregions.DNA immobilization: double-stranded (ds)biotinylatedRACE-derived PCR
products are bound to streptavidin-coupled magnetic beads. After the DNA–beads complex is immobilized on a magnetic stand, ssDNA is prepared by NaOH
denaturation. Cleavage of ssDNA: annealing of the adapter oligonucleotides to the top strand retained on the beads creates a dsDNA region accessible for the
restriction enzyme (E1). Cleaved single-stranded V gene is released from the beads and can now be used in the next step. Preparation of the V-gene ssDNA for
cloning: The ssDNA is then ligated to a 100· excess of partially dsDNA made through the annealing of two oligonucleotides. The lower-strand tail of this
oligonucleotideduplexiscomplementaryto the 50 endofthe ssDNA,allowingtheirrecognitionduringthe ligationprocedure.Theligatedproductisthenamplified
usingprimersappendedwithappropriaterestrictionsites(plainblackarrows),allowingthedirectionalcloningoftheVgenesintothephagemidvector.Erepresents
restrictionenzymes,verticalrectanglesrepresentrestrictionsites,asterisksrepresentbiotin,darkrectanglesrepresentthetailedsequenceand‘base-adorned’arrows
represent base pairing of the oligonucleotides with the ssDNA. (B) Example of ONCL method: l1 V-gene capture and cloning. (1) Annealing of adapter for family
Vl1t oV l1 genes, immobilized on beads—cleavage by HinfI; (2) release of cleaved Vl1 genes in supernatant; (3) annealing and ligation of cleaved Vl1 genes to
hybridizedVl1bridgeandextender(ApaLIsiteunderscored);(4)amplificationofligatedDNAusingONPlePCRandCl2,7forAscprimers;(5)directionalcloning
into pMid21 of Vl1 genes via ApaLI and AscI. X, non-V-gene related amino acid sequence.
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raries made by cloning of PCR fragments: 7.8 · 10
9 indi-
vidual clones for the k light chains and 2.3 · 10
9 clones
for the l ones into pMID21 phagemid vector. The heavy
chain repertoire was then introduced into both light chain
libraries. A Fab phage-display library carrying k chains was
then created of 5 · 10
9 transformants; the l chain library
contains3.2 · 10
10Fabclones.PCR screening of48 randomly
selected clones showed that all carry full-length Fab-encoding
inserts.
Quality control of the library by DNA sequencing. We
evaluated the quality of the library by sequencing 84 clones.
Our results showed that 70% of the Fab sequences are correct,
while single or multiple mutations are present in 30%
of the sequences. We found that this was mainly due to
incorrect synthetic oligonucleotides or misannealing causing
frameshifts.
The VH distribution. To validate our technology, we ﬁrst stud-
ied the distribution of the different VH families in our ﬁnal
library. As a reference, we took the frequency of the VH
families in the IgG repertoire of healthy donors described
by de Wildt et al. (32), where the authors showed that the
VH 1, 3 and 4 families are the most commonly represented in
PBLs. We initially determined the sequences of the heavy
chains of 35 clones randomly picked from our library. The
sequences were aligned with the germ-line VH gene database
in order to determine their VH family afﬁliation. We observed
that 17% are representative for family VH 1, 6% for VH 2, 9%
for VH 3, 51% for VH 4, 14% for VH 5 and 3% for VH 6. When
compared with the distribution in healthy donors, our library
had an over-representation of family 4, while family 3 is sur-
prisingly under-represented, suggesting biases induced either
through ONCL technology or caused by the modiﬁcation of
the human PBL expression in the Trimera mouse system. In
order to understand the origin of this uncommon VH distribu-
tion, we determined the sequences of 73 additional heavy
chains of the ONCL library together with 115 heavy chains
of the ampliﬁed V genes before the ONCL cleavage and
aligned them to the germ-line VH gene database. As depicted
in Figure 4A, the VH distributions observed before (RACE-
derived clones) and after the ONCL cleavage are comparable,
demonstrating that the VH distribution we observed is not the
consequence of our ONCL technology but most probably
arose through the Trimera mouse system or the C.albicans
infection. Furthermore, as shown in Figure 4B, some VH
gene segments (4-61, 4-39 and 4-59) seem to be over-
represented when compared with 292 VH sequences collected
by Tomlinson et al. (33), showing that the pattern of usage of
the segments in Trimera mice spleens (or in C.albicans infec-
ted patient PBLs) appears to differ from the usage in healthy
donor samples.
Isolation and characterization of specific anti-GAPDH
Fab antibodies
SelectionandELISAscreening.Theperformance ofthelibrary
was evaluated by selecting for binders to baculovirus-
produced C.albicans GAPDH antigen. Two selection strat-
egies were employed. The ﬁrst used biotinylated GAPDH
antigen bound to streptavidin-coupled magnetic beads, and
the second was performed on GAPDH-coated immunotubes.
Three rounds of selection were then performed for each strat-
egy. From rounds 2 and 3 of each selection campaign, 96
individual phage clones were screened for reactivity with
the biotinylated and coated GAPDH by ELISA. Biotinylated
BSA bound to streptavidin was used as a negative control in
the ELISA. The frequencies of positive phage ELISA clones at
round 3 were 2 and 51%, for the ﬁrst and the second method,
respectively.
The number of distinct Fabs was analyzed by DNA
sequence determination of both light and heavy chains.
Two distinct Fab sequences were found for the ﬁrst method
of selection, and three distinct sequences were found for the
second method. Their CDR amino acid sequences are presen-
ted in Table 2 and are compared with human germ-line genes.
The selected anti-GAPDH antibodies belong to families VH 1,
3 and 5; twoof them are related to VH segment 1-02, one to VH
segment 3-23, one to VH segment 3-30 and one to VH segment
5-51. A comparison of mutations occurring at the amino
acid sequence level is shown for clones B1 and C1 in Table 3.
Figure 3. ONCL capture of V-gene repertoires. (A) Analysis of the cleavage
efficiency of l (left panel) and k (right panel) light chains using the ONCL
cleavage protocol outlined in Figure 2A. In lanes 2, ssDNA left on beads after
the HinfI ONCL cleavage (l chains, left panel) or the BsmAI cleavage (k
chains, right panel) and in lanes 3 cleaved ssDNA fragments released in the
supernatant after the cleavage. The smaller band in both lanes 2 represents an
artifact as it appears even in the uncleaved material (data not shown). Equiva-
lentfractionsofeachsampleswereanalyzedon5%TBE-ureaPAGEgels(Bio-
Rad) together with the low DNA mass markers (M) and 100 bp (lanes 1)
(Invitrogen).(B)AnalysisofthecleavageefficiencyofheavychainsafterPvuII
(left panel) and AvaII (right panel) ONCL cleavages. ssDNA immobilized on
beadsbeforeanyONCLcleavage(lanes1,leftandrightpanels),ssDNAlefton
beads, respectively, after the PvuII ONCL cleavage (lane 2, left panel) or the
AvaII one (lane 2, right panel), and cleaved ssDNA fragments released in the
supernatant after the cleavage (lanes 3) are analyzed. Equivalent fractions of
each sample were analyzed on 5% TBE-urea PAGE gels (Bio-Rad) together
with the low DNA mass markers (M) (Invitrogen).
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the heavy chain framework 1, CDR 2 and CDR 3.
Specificity analysis of the selected monoclonal Fabs. The
speciﬁcity of candidate clones selected from the library was
further conﬁrmed by ELISA as both phage-displayed Fab
product and soluble Fab product, directly collected from
cell supernatant or FPLC-puriﬁed (Figure 5). To allow soluble
Fabproduction, the positive phage antibodies were recloned as
described in Materials and Methods. Soluble Fabs were then
produced at high yields from E.coli periplasm. The average
yield of soluble recombinant protein after metal chelate chro-
matography puriﬁcation was  100–400 mg puriﬁed Fab/L
bacterial culture using shaker ﬂasks. The speciﬁcity of the
anti-GAPDH clones for binding to their target was then
checked using ELISA (Figure 5). Two of the ﬁve speciﬁc
phage antibodies (B1 and C1) were found reactive on
GAPDH antigen as soluble Fab.
In summary, we have validated the novel ONCL technology
ﬁrst by the successful construction of an immune phage-
display antibody library, then by the comparison of the IgG
captured repertoires with IgG repertoires cloned by standard
technologies.Moreover,wehaveshownthatthislibraryisfunc-
tional through the isolation of ﬁve anti-GAPDH antibodies.
DISCUSSION
This report describes a novel approach to capture unbiased
cDNA libraries, the ONCL method. Previously published
methods for capturing Ig gene fragments have biases that
ONCL avoids. We report an evaluation of ONCL through
the construction of an immune phage-display library and
selection of speciﬁc Fabs. We validated this new method
by analyzing the antibody sequences of the library. We
demonstrated that the ONCL cleavage of DNA in single-
strand form is very effective, yielding a correct ampliﬁcation
product of the desired length, without any contaminating DNA
populations. ONCL is the ﬁrst technology that enables cleav-
age of linear ssDNA through the assistance of oligonucleotides
and restriction enzymes to capture a gene repertoire where the
gene family contains suitable restriction sites in all members.
ONCL combines numerous advantages compared with
other protocols for antibody library construction currently
in use. In this strategy, using the 50 RACE as the ﬁrst amp-
liﬁcation step circumvents the biases introduced by speciﬁc
PCR primers when located in the immunoglobulin 50 variable
region itself. Although antibody diversity resides mainly in the
CDR regions, several reports have shown diversity within the
framework regions, which may also be important for the bind-
ing to the target (18,19). Priming in a non-V-gene sequence
potentially allows the capture of a wider repertoire. As expec-
ted, the antibody repertoire we captured was found to be
diverse both in CDR and in framework regions. In the
small sampling of RACE-derived samples that we examined,
we saw the antibody repertoire was assembled from all the
major VH families (Figure 4B). The complexity of the reper-
toire might be affected by the 50–70 rounds of ampliﬁcation,
required to obtain enough material for the cleavage. In com-
parison, PCR-made phage-display libraries have been built
after 60–80 PCR cycles (3,8–14) and diversity in those
A
B
Figure 4. VH family distribution analysis. (A) Frequency of VH family use in
healthy donor samples compared with Trimera mice samples (RACE-derived
and ONCL-cleaved samples). VH family distribution was compiled for the
healthy donor samples from the 265 VH described by de Wildt et al. (32),
was studied in 1254 collected heavy chain sequences (VH database) (R. C.
Ladner, unpublisheddata) in 115 clones of RACE-derived VH genes, and in 73
clones of the VH repertoire from the immune library. (B) Use of human germ-
lineV-genesegments.FrequenciesofuseofhumanVHsegmentswascompiled
fromthe292rearrangedVHgenesinthedatabasedescribedbyTomlinsonetal.
(33),observedin115clonesofTrimeramice-amplifiedandRACE-derivedVH
genes, and in 73 clones of the VH repertoire from the immune library.
Frequencies (f) are plotted as % of total.
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number of PCR cycles is performed in the ONCL protocol,
we expect the diversity to be at least equivalent. Furthermore,
in conventional PCR-derived libraries, the use of V-gene-
speciﬁc primers can affect the complexity of the repertoire
by compromising the ampliﬁcation of low expressed genes or
genes that differ from germline in the priming region. In con-
trast, ONCL uses non-V-gene related primers in all ampliﬁca-
tion steps. This allows the maintenance of the initial gene
proportionsinthe repertoireandthereforeincreasesthechance
of capturing rare mRNAs. As a main result, the probability of
encompassing the entire antibody diversity is enhanced and
complexity is very likely to be higher than in PCR-made
libraries. This is important when analyzing RNA from hetero-
geneous B-cell populations. When we compared the heavy
chain repertoire present in the library with the rearranged
VH segment gene database described by Tomlinson et al.
(33), we observed that human VH segments not frequently
used were captured, such as 1-02, 3-21, 3-49, 4-30-4 and
5-a segments (Figure 4B). This usage of infrequently seen VH
gene segments could be driven by the C.albicans anti-GAPDH
immune response, note that two of the ﬁve selected anti-
GAPDH antibodies shared the 1-02 VH segment.
Although the restriction enzymes used in ONCL may recog-
nize only four bases, the cleavage has an effective speciﬁcity
equaltothelengthoftheadapteroligonucleotides. Theanneal-
ing of the adapter can tolerate one or two base errors as long as
the restriction site is maintained. The annealing and ligation
of the bridge–extender can also tolerate one or more errors.
Thus, the cleavage is precise while preserving diversity in the
framework.
As with PCR technology, ONCL gives preference for
complete 50 regions because the oligonucleotide adapter
will not anneal to truncated antibody gene fragments. This
enables sequences that have deletions to be removed from
the ampliﬁed DNA before displaying. Also, after RACE, all
V-gene sequences that we analyzed showed full-length coding
regions, including leader sequences. In contrast to PCR tech-
nology, this new technology offers the advantage of monitor-
ing the cleavage efﬁciency and, therefore, the V-gene capture
efﬁciency through the set of designed adaptors. Moreover, as
ONCL requires DNA in a single-stranded format and its
hybridization to appropriate oligonucleotide adapters,
ONCL excels classical strategies that depend on PCR and
restriction enzyme cleavage that would fail to succeed for
the cloning of genes containing multiple and identical restric-
tion enzyme sites.
A possible limitation of this novel cleavage approach is that
the set of designed adapters might not anneal and capture all
V genes. However, in our experiments, the heavy chain
Table 3. Deduced protein sequences of anti-GAPDH antibody fragments: comparison of heavy chain protein sequence from clones B1 and C1
 
 
 
 
 
                 FR1                  CDR1          FR2              CDR2       
------------------------------ ------- -------------- -------------------
    1         2         3               4           5            6 
    123456789012345678901234567890  1ab2345  67890123456789  012abc3456789012345
B1  EVQLVQSGAEVKKPGASVKVSCKSSGYTFT  G--YYIY  WVRQAPGQGLEWLG  WINP--DSGGTNYAQKFHD
C1  EVQLVQSGAEVKKPGASVRVSCKSSGYTFT  G--YYIY  WVRQAPGQGLEWLG  WINP--DSGGTNYARKFHD
                      FR3                     CDR3         FR4            
-------------------------------- -------------- -------
          7         8            9 
      67890123456789012abc345678901234
      RVTMTRDTSVSTAYLELSSLRSDDTAVYYCAR  ATVSMTRGLFYYLED  WGQ
RVTMTRDTSVSTAYLELSSLRSDDTAVYYCAR  ATVSMIRGLFYYLED  WGQ
Mutations are underlined. FR, framework region; and CDR, complementarity determining region.
Table 2. Deduced protein sequences of anti-GAPDH antibody fragments: CDR domains, V-gene family and germ-line (derivation)
Anti-GAPDH clone LC-CDR1 LC-CDR2 LC-CDR3 Family/germline
R2 G5 RASQSISSYLN AASSLQS QQSYSTPRT K1/DPK9
R2 C12 RSSQSLVYSDGNTYLN KVSNRDS MQGTHWPRT K2/DPK18
R3 B1 SGSSSNIGTNYVY RNNQRPS AAWDDSLGGRV L1/DLP3
R3 C1 SGSSSNIGTNYVY RNNQRPS AAWDDSLGGRV L1/DLP3
R3 F5 RASQSISSSYLA GASSRAT QQYDSSSVT K3/DPK22
HC-CDR1 HC-CDR2 HC-CDR3
R2 G5 DFGIT RISPTDSYTMYSPSFQG HRGAPYDYDSGGPYDYYGMDV VH5/5-51
R2 C12 SYGMH VTAHDGTNKYYADSVKG VAGAYGENSWYFDV VH3/3-30
R3 B1 GYYIY WINPDSGGTNYAQKFHD ATVSMTRGLFYYLED VH1/1-02
R3 C1 GYYIY WINPDSGGTNYARKFHD ATVSMIRGLFYYLED VH1/1-02
R3 F5 RYRMA SIVPSGGRTFYADSVKG NARRAFPSMDV VH3/3-23
CDR, complementarity determining region.
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VH segments when captured by the 50 RACE after the ONCL
cleavage (Figure 4B), conﬁrming the correct design of the
cleavage adapters. The slight differences observed between
both repertoires are likely to be the result of a limited sequence
sampling (Figure 4B). As two VH germ-line gene sequences
lack PvuII restriction sites (1-03 and 4-34), these VH members
are not likely to be captured. However, these two VH genes are
normally used at a very low frequency by the human reper-
toire, so the overall quality of the VH repertoire will not be
affected (32).
The ONCL cleavage is performed at high temperatures
(>50 C) to maintain DNA in a single-stranded form. One
might think that using these high temperatures could affect
the enzymatic properties of type II restriction enzymes, for
which lower temperature are recommended. However, we
showed that efﬁciency of cleavage was maintained even for
temperatures above 50 C.
The library was found to contain 70% of antibodies with a
full read-through sequence and 30% with stop codons, mostly
derived from incorrectly synthesized oligonucleotides, misan-
nealing or from the PCR steps. When constructing libraries
using standard PCR procedures, these types of mutations also
arise. Likewise, the fact that we are using synthetic oligonuc-
leotides in the bridge–extender ligation of the ONCL-cleaved
V genes (Figure 2) also generated a few incorrect sequences
that wefoundtobemainlyduetothe oligonucleotide synthesis
itself. Nevertheless, these are compensated for by the con-
struction of a very large size immune library of 3.3 · 10
10
transformants.
We observed an over-representation of VH family 4 and an
under-representation of VH family 3. The most frequent heavy
chain germ-line gene V3-23 was almost absent in our samples,
whereas three VH4 family members 4-61, 4-39 and 4-59 were
frequently observed (Figure 4B). Since the human PBLs used
to engraft the Trimera mice were isolated from four patients, it
is very unlikely that V3-23 would be under-represented and
VH4-61, 4-39 and 4-59 over-represented in all four donor
samples, although we cannot fully exclude this possibility.
Furthermore, one of the ﬁve selected anti-GAPDH antibodies
uses the VH3-23 segment, reinforcing our hypothesis that this
bias is related to the use of the Trimera mouse system.
Although human antibodies speciﬁc for several viral patho-
gens were successfully isolated using phage combinatorial
libraries constructed from individuals with a positive serum
titer against a given antigen (34), the use of the Trimera mouse
system was guided by the additional idea to use it as a tool to
boost the human IgG immune response against a speciﬁc anti-
gen. ELISA data performed with stimulated mouse sera con-
ﬁrm this was effective. Moreover, two reports support the
differences we observed in the VH segment usage found in
the IgG repertoire we isolated from GAPDH-immunized Tri-
mera mice when compared with IgG repertoires derived either
from normal or autoimmune individuals (32,35). Therefore,
we think that this preferential VH gene use ismost likely due to
B-cell triggering in the Trimera mouse system. However, we
cannot exclude the possibility that the use of a novel antibody
cloningtechnique(ONCL),which overcomes thevariabilityin
the B-cell repertoire, may have resulted in a more accurate
representation of human VH families as compared with pre-
viously reported technologies (32,33).
The human immune response, both in humans and in mice,
results in antibodies that bind a rather limited number of pro-
tective epitopes (10), and immunization leads to the recogni-
tion only of a limited number of immunodominant epitopes.
The diversity of immunoglobulin genes in an immune library
is therefore expected to be limited compared with a non-
immune library (IgM repertoire). In our case, the source of
antibody-producingBcellswasperipheralblood lymphocytes,
which are mainly IgM-positive cells coming from C.albicans-
infected patients. Although the frequency of IgG B cells activ-
ated against GAPDH was therefore expected to be rather low,
the engrafted Trimera mice showed a clear IgG anti-GAPDH
serum antibody titer, indicating the immune response directed
to C.albicans GAPDH was enhanced in the Trimera mice. In
a parallel work, the ONCL method has also been successfully
used to build a non-immune library (36).
In addition, we have established the functionality of the
ONCL library through the isolation of ﬁve speciﬁc anti-
GAPDH antibodies. The two different selection strategies
that we used gave different results, correlating with the ﬁnd-
ings of Lou et al. (37). The sequences of two of those ﬁve
antibodies show signiﬁcant identity (B1 and C1). This sug-
gests that the B cells producing them were derived from the
same pre-existing B-cell clone and indicates that the obtained
anti-GAPDH antibodies are originating from a human immune
(IgG) repertoire. However, although the proof-reading activity
of Advantage 2 polymerase should reduce the mutation rate by
3-fold compared with a regular Taq polymerase, we cannot
exclude mutations due to PCR ampliﬁcation.
In summary, we have established a new cloning technology,
the ONCLmethod, formakingantibody librariesandvalidated
it by isolating C.albicans-speciﬁc antibodies from immunized
mice carrying human B-lymphocytes. The cornerstone of the
technology, oligonucleotide-directedcleavage of ssDNA, isan
Figure 5. Specificity of selected anti-GAPDH antibody fragments determined
by ELISA. Characterization of phage and soluble Fab anti-GAPDH antibodies
by ELISA.Theassaywasperformedby immobilizing biotinylated GAPDHon
a polystyrene plate. Phage-displayed antibodies reactive with the coated anti-
gen were detected with peroxidase-conjugated anti-M13 antibody (Amer-
sham), while the detection of soluble Fabs was performed using 9E10 anti-
c-myc monoclonal antibody (final concentration 2 mg/ml) followed by
peroxidase-conjugated rabbit anti-mouse antibody (1:1000). The results of
the assay are shown as absorbance at 450 nm. In the case of the data obtained
with the phage preparation and the sFab cell supernatant, results were not
normalized for protein concentrations.
e81 Nucleic Acids Research, 2005, Vol. 33, No. 9 PAGE 12 OF 14alternative to PCR for the directional cloning of groups of
related mRNAs, such as those of immunoglobulins and T-
cell receptors. Besides the demonstrated application for the
cloning of human antibody libraries as established here, we
anticipate that the concept of oligonucleotide-assisted ssDNA
cleavage will be applicable in cDNA cloning of repertoires of
related genes, enzymatic restriction of DNA molecules con-
taining multiple identical restriction sites, general strategies of
mutagenesis, antibody afﬁnity maturation (chain or CDR
shufﬂing) and library design.
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